Roche: gets European priority status for lymphoma drug.
(CercleFinance.com) - Roche said on Friday that European authorities have granted priority designation status for a combination of drugs in the treatment of relapsed or refractory diffuse large B cell lymphoma.
The Swiss drugmaker today announced that the European Medicines Agency (EMA) granted this status to the company's investigational medicine polatuzumab vedotin in combination with MabThera (rituximab) and bendamustine for the treatment of the disease, the most common aggressive form of non-Hodgkin lymphoma.
It is estimated that as many as 40% of patients with the disease experience a relapse following initial treatment.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The Swiss drugmaker today announced that the European Medicines Agency (EMA) granted this status to the company's investigational medicine polatuzumab vedotin in combination with MabThera (rituximab) and bendamustine for the treatment of the disease, the most common aggressive form of non-Hodgkin lymphoma.
It is estimated that as many as 40% of patients with the disease experience a relapse following initial treatment.
Copyright (c) 2017 CercleFinance.com. All rights reserved.